drugset / Trial / NCT01309438

A Study of Erythromycin and Rivaroxaban in Study Participants With Normal and Reduced Kidney Function

NCT01309438

Parallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the pharmacokinetics and pharmacodynamics of rivaroxaban when administered with erythromycin to study participants with mild or moderate renal impairment compared to the pharmacokinetics and pharmacodynamics of rivaroxaban administered to study participants with normal renal function.

Timeline

Start
2011-02
Primary completion
2012-03
Completion
2012-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Erythromycin Small molecule 500 mg Oral
Subject Rivaroxaban Other / unclassified 5 mg Oral
Subject Rivaroxaban Other / unclassified 10 mg Oral